On-line version ISSN 2078-5151
Print version ISSN 0038-2361
S. Afr. j. surg. vol.50 n.3 Cape Town Aug. 2012
W S WiggettI; M LouwII; V O L KarusseitIII
IMB ChB, MMed (Surg); Department of Surgery, University of Pretoria and Steve Biko Academic Hospital, Pretoria
IIMB ChB, MMed (Anat Path); Department of Anatomical Pathology, University of Pretoria, and National Health Laboratory Service, Tshwane Academic Division
IIIMB ChB, MFGP (SA), MMed (Surg), FCS (SA); Department of Surgery, University of Pretoria and Steve Biko Academic Hospital, Pretoria
INTRODUCTION: Surgery is sometimes performed on patients with peau d'orange (dermal oedema) of the breast. This may be done to achieve local control of cancer after neo-adjuvant chemotherapy or in resectable locally advanced disease. Conventional practice is not to place excision lines through areas of peau d'orange for fear of recurrence in such an area. The question can be asked whether this wisdom is still valid in modern practice. No formal cohort studies documenting the histopathology of the skin in areas of peau d'orange have been published, and available descriptions are scanty.
AIM: To describe the histopathological features of peau d'orange.
METHOD: Consecutive patients undergoing mastectomy for cancer in whom peau d'orange was present were selected over a period of 2 years. Blocks of skin were excised from areas of peau d'orange and examined histologically. The presence, nature and location of malignant cells were recorded and correlated with lymph node pathology. Prior administration of neo-adjuvant chemotherapy was noted.
RESULTS: Twenty-six mastectomy specimens were examined. Tumour islands in lymphatics were identified in 10 of the 26 specimens. These tumour groups were found in lymph vessels of both the superficial and deep dermal plexuses. In 1 specimen the presence of malignant cells was equivocal. Metastatic tumour was present in axillary lymph nodes in 19 of 22 specimens. Fourteen patients had been treated with neo-adjuvant chemotherapy, and 5 of their specimens exhibited the presence of tumour cell groups in lymphovascular channels.
CONCLUSION: Tumour cells were present in the lymphatic vessels in areas of peau d'orange in 38% of the specimens studied. It would be expected that placing an excision line in such an area would result in an incomplete cancer operation in a high percentage of, but not all, cases.
“Full text available only in PDF format”
1. Haagensen C, Stout A. Carcinoma of the breast: criteria for operability. Ann Surg 1943;118:859-868. [ Links ]
2. Haagensen CD. Diseases of the Breast. 3rd ed. Philadelphia: WB Saunders, 1986. [ Links ]
3. Shenkier T, Weir L, Levine M, Olivotro I, Whelan T, Reyno L. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ 2004;170(6):983-994. [ Links ]
4. Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast. Cancer 1974;33:1045-1047. [ Links ]
5. Gruber G, Ciriolo M, Altermatt HJ, Aebi S, Berclaz G, Greiner RH. Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer 2004;109:144-148. [ Links ]
6. Rosen PP. Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance. Pathology Annual 1983;18(2):215-232. [ Links ]
7. Kwak JY, Kim E, Chung SY, et al. Unilateral breast edema: spectrum of etiologies and imaging appearances. Yonsei Med J 2005;46(1):1-7. [ Links ]
8. Horvath Z, Torday L, Hitre E, et al. Inflammatory breast cancer - comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional anthracycline-containing chemotherapy to achieve clinical benefit and complete pathlogical response. Pathol Oncol Res 2011;17:541-550. [ Links ]
9. Mailliez A, Baranzelli MC, Giard S, et al. Is there a reliable method to assess the complete pathologic response on the tumor after neo-adjuvant chemotherapy in inflammatory breast cancer toward recommendations for the pathologic process? Experience in 56 patients treated in a single institution. Breast J 2010;16:464-471. [ Links ]
10. Sinn HP, Schmid H, Junkerman H, et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe und Frauenheilkunde 1994;54(10):552-558. [ Links ]
11. Handley RS. The Anatomy of the Breast: Breast Cancer and its Diagnosis and Treatment. Baltimore: Williams & Wilkins, 1955. [ Links ]
12. Kuhns JG, Ackerman DM. Macroscopic anatomy of the breast. In: Donegan WL, Spratt JS, eds. Cancer of the Breast. 5th ed. St Louis: Saunders, 2002. [ Links ]
13. Orbo A, Stalsberg H, Kunde D. Topographic criteria in the diagnosis of tumor emboli in intramammary lymphatics. Cancer 1990;66:972-977. [ Links ]
14. Nime FA, Rosen PP, Thaler HT, Ashikari R, Urban JA. Prognostic significance of tumor emboli in intramammary lymphatics in patients with mammary carcinoma. Am J Surg Pathol 1977;1(1):25-30. [ Links ]
15. Moore DH, Rouse MB, Massenburg GS, Zeman EM. Description of a spheroid model for the study of radiation and chemotherapy effects on hypoxic tumor cell populations. Gynecol Oncol 1992;47:44-47. [ Links ]
16. Alpaugh ML, Tomlinson JS, Ye Y, Barsky SH. Relationship of sialyl-Lewisx/a underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast cancer. Am J Pathol 2002;161(2):619-628. [ Links ]
17. Harris EL, Lewin DN, Wang HL, et al. Lymphovascular invasion in colo-rectal cancer. An interobserver variability study. Am J Surg Pathol 2008;32(12):1816-1821. [ Links ]
18. Gilchrist KW, Gould VE, Hirschl S, et al. Interobserver variation in the identification of breast carcinoma in intramammary lymphatics. Hum Pathol 1982;13(2)170-172. [ Links ]
19. Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 2006;94(11):1643-1649. [ Links ]
20. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011;22(3):515-523. [ Links ]